Barclays Maintains Overweight on Elevance Health, Raises Price Target to $621
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Andrew Mok maintains an Overweight rating on Elevance Health (ELV) and raises the price target from $584 to $621.
April 19, 2024 | 12:36 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Barclays maintains an Overweight rating on Elevance Health and raises the price target from $584 to $621.
The upgrade in the price target by Barclays reflects a positive outlook on Elevance Health's stock, suggesting confidence in the company's future performance. This analyst action can lead to increased investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100